295 related articles for article (PubMed ID: 18289433)
1. Advances in understanding sepsis.
Shimaoka M; Park EJ
Eur J Anaesthesiol Suppl; 2008; 42():146-53. PubMed ID: 18289433
[TBL] [Abstract][Full Text] [Related]
2. Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department.
Sama AE; D'Amore J; Ward MF; Chen G; Wang H
Acad Emerg Med; 2004 Aug; 11(8):867-73. PubMed ID: 15289194
[TBL] [Abstract][Full Text] [Related]
3. The vagus nerve and the inflammatory reflex: wandering on a new treatment paradigm for systemic inflammation and sepsis.
Huston JM
Surg Infect (Larchmt); 2012 Aug; 13(4):187-93. PubMed ID: 22913335
[TBL] [Abstract][Full Text] [Related]
4. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis.
Huston JM; Gallowitsch-Puerta M; Ochani M; Ochani K; Yuan R; Rosas-Ballina M; Ashok M; Goldstein RS; Chavan S; Pavlov VA; Metz CN; Yang H; Czura CJ; Wang H; Tracey KJ
Crit Care Med; 2007 Dec; 35(12):2762-8. PubMed ID: 17901837
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory therapies in sepsis.
Kox WJ; Volk T; Kox SN; Volk HD
Intensive Care Med; 2000; 26 Suppl 1():S124-8. PubMed ID: 10786969
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic targets for sepsis: regulation of exaggerated inflammatory responses.
Matsuda A; Jacob A; Wu R; Aziz M; Yang WL; Matsutani T; Suzuki H; Furukawa K; Uchida E; Wang P
J Nippon Med Sch; 2012; 79(1):4-18. PubMed ID: 22398786
[TBL] [Abstract][Full Text] [Related]
7. Cholinergic regulatory lymphocytes re-establish neuromodulation of innate immune responses in sepsis.
Peña G; Cai B; Ramos L; Vida G; Deitch EA; Ulloa L
J Immunol; 2011 Jul; 187(2):718-25. PubMed ID: 21666060
[TBL] [Abstract][Full Text] [Related]
8. An ongoing search for potential targets and therapies for lethal sepsis.
Bao GQ; He L; Lee D; D'Angelo J; Wang HC
Mil Med Res; 2015; 2():20. PubMed ID: 26257917
[TBL] [Abstract][Full Text] [Related]
9. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis.
Pavlov VA; Ochani M; Yang LH; Gallowitsch-Puerta M; Ochani K; Lin X; Levi J; Parrish WR; Rosas-Ballina M; Czura CJ; Larosa GJ; Miller EJ; Tracey KJ; Al-Abed Y
Crit Care Med; 2007 Apr; 35(4):1139-44. PubMed ID: 17334244
[TBL] [Abstract][Full Text] [Related]
10. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis.
Oberholzer A; Souza SM; Tschoeke SK; Oberholzer C; Abouhamze A; Pribble JP; Moldawer LL
Shock; 2005 Jun; 23(6):488-93. PubMed ID: 15897799
[TBL] [Abstract][Full Text] [Related]
11. The role of high mobility group box-1 protein in severe sepsis.
Sunden-Cullberg J; Norrby-Teglund A; Treutiger CJ
Curr Opin Infect Dis; 2006 Jun; 19(3):231-6. PubMed ID: 16645483
[TBL] [Abstract][Full Text] [Related]
12. Is neuroimmunomodulation a future therapeutic approach for sepsis?
Kumar V; Sharma A
Int Immunopharmacol; 2010 Jan; 10(1):9-17. PubMed ID: 19840870
[TBL] [Abstract][Full Text] [Related]
13. Selective Activation of Basal Forebrain Cholinergic Neurons Attenuates Polymicrobial Sepsis-Induced Inflammation via the Cholinergic Anti-Inflammatory Pathway.
Zhai Q; Lai D; Cui P; Zhou R; Chen Q; Hou J; Su Y; Pan L; Ye H; Zhao JW; Fang X
Crit Care Med; 2017 Oct; 45(10):e1075-e1082. PubMed ID: 28806219
[TBL] [Abstract][Full Text] [Related]
14. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?
Boomer JS; Green JM; Hotchkiss RS
Virulence; 2014 Jan; 5(1):45-56. PubMed ID: 24067565
[TBL] [Abstract][Full Text] [Related]
15. Experimental therapeutic strategies for severe sepsis: mediators and mechanisms.
Parrish WR; Gallowitsch-Puerta M; Czura CJ; Tracey KJ
Ann N Y Acad Sci; 2008 Nov; 1144():210-36. PubMed ID: 19076379
[TBL] [Abstract][Full Text] [Related]
16. The systemic inflammatory response syndrome.
Weigand MA; Hörner C; Bardenheuer HJ; Bouchon A
Best Pract Res Clin Anaesthesiol; 2004 Sep; 18(3):455-75. PubMed ID: 15212339
[TBL] [Abstract][Full Text] [Related]
17. The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment.
Haveman JW; Muller Kobold AC; Tervaert JW; van den Berg AP; Tulleken JE; Kallenberg CG; The TH
Neth J Med; 1999 Sep; 55(3):132-41. PubMed ID: 10509072
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory response and immune regulation of high mobility group box-1 protein in treatment of sepsis.
Liu QY; Yao YM
World J Emerg Med; 2010; 1(2):93-8. PubMed ID: 25214948
[TBL] [Abstract][Full Text] [Related]
19. High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor.
Czura CJ; Yang H; Tracey KJ
J Infect Dis; 2003 Jun; 187 Suppl 2():S391-6. PubMed ID: 12792856
[TBL] [Abstract][Full Text] [Related]
20. The puzzle of sepsis: fitting the pieces of the inflammatory response with treatment.
Cunneen J; Cartwright M
AACN Clin Issues; 2004; 15(1):18-44. PubMed ID: 14767363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
